PerkinElmer, Inc. has announced an agreement to acquire the leading antibody and research reagent provider, BioLegend, Inc. for around $5.25 billion. This will be the largest acquisition in PerkinElmer’s history.
In a statement released by PerkinElmer, the deal will be made up of a combination of cash and stock. Goldman Sachs Bank USA will provide bridge financing facility to accommodate the cash portion of the acquisition. PerkinElmer is expecting the deal to conclude by the end of this calendar year, subject to regulatory conditions.
Exciting Prospect of BioLegend
BioLegend develops top-tier antibodies and reagents for academics and biopharmaceutical customers. The company is focusing the development on innovative and high growth areas of biologics, cell and gene therapy, prote…